QPS

China's 01.AI Launches Top-Performing Vector Database "Descartes" for LLM

Retrieved on: 
Monday, March 11, 2024
Vector, Microsoft, Database, Algorithm, RAG, Knowledge, Meta, Tree (graph theory), Infrastructure, AI, Ultra, LLM, QPS, Hallucination, René Descartes, Conifer cone, Privacy, Multimedia, Medical device

01.AI's vector database, named "Descartes," has topped the rankings in six data set evaluations on the mainstream ANN-Benchmarks.

Key Points: 
  • 01.AI's vector database, named "Descartes," has topped the rankings in six data set evaluations on the mainstream ANN-Benchmarks.
  • In the Large Language Model (LLM) technology stack, a vector database is an important component in connecting external information with LLMs.
  • Currently, the focus of 01.AI's Descartes Vector Database is on high-performance vector databases.
  • The new vector database capabilities will be effectively applied in the company's AI productivity consumer product launching soon.

Superbrewed Food is the World’s First Company to Receive U.S. FDA No-Questions for Bacteria Biomass Protein and to Progress in Global Jurisdictions

Retrieved on: 
Wednesday, March 6, 2024
Professional Services, Patent Law, Retail, Health, FDA, Venture Capital, Food, Beverage, IMAGE, EFSA, Multimedia, Zinc, Generally recognized as safe, Temperature, European, Partnership, Vitamin, Animal, GRAS, Letter, Probiotic, Sport, QPS, Human, Drink, Patent, Bel Group, Nutritional science, Credit, Environment, Iron, Dietary supplement

View the full release here: https://www.businesswire.com/news/home/20240306922266/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306922266/en/
    Superbrewed Food Postbiotic Cultured Protein and Beverage made with Postbiotic Cultured Protein.
  • GRAS is a designation created by the FDA under the Federal Food, Drug and Cosmetic Act.
  • Superbrewed has filed applications for market authorization of Postbiotic Cultured Protein as a “novel food” in the European Union, Great Britain and Canada.
  • Postbiotic Cultured Protein is over 85% protein, with a high content of essential and branched-chain amino acids.

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity

Retrieved on: 
Wednesday, January 10, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CITES, Mass spectrometry, UPLC, Multimedia, QPS, Peptide, DMPK, Drug discovery, LC-MS, Laboratory, Therapy, Doctor of Philosophy, Biomarker, HRMS, Oligonucleotide, SFC, Growth, Fine chemical

QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).

Key Points: 
  • QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
  • View the full release here: https://www.businesswire.com/news/home/20240110198636/en/
    Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • (Photo: Business Wire)
    This expansion includes the impressive growth seen in 2023, when QPS installed seven additional UPLC-(HR)MS/MS tandem instruments - four triple quadrupoles, one QTRAP, and two quadrupole time-of-flight high-resolution mass spectrometers (HRMS).
  • QPS Subject Matter Experts are some of the best in the industry and this new equipment will provide the capacity for them to expand their relationships with our important biotech and pharmaceutical clients,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

QPS Holdings, LLC Expands Operations in Springfield, Missouri

Retrieved on: 
Monday, December 4, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pharmacist, Administration, Contract research organization, Clinical trial, Hematology, QPS, Safety, Urinalysis, Multimedia, Pharmacy, Physician, Pharmaceutical industry, Chemistry, Serology

QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri.

Key Points: 
  • QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri.
  • The 2,750-square-foot facility is fully operational as of the fall of 2023 and will give QPS significant flexibility in clinical research study operations.
  • View the full release here: https://www.businesswire.com/news/home/20231204471818/en/
    QPS Missouri is a division of QPS Holdings, LLC, a global Contract Research Organization.
  • QPS Missouri conducts Phase I-IV clinical trials in Springfield, Missouri, and has recently added a new safety laboratory, updated pharmacy, and clinical trial kit production facility.

QPS Holdings, LLC divests its Neuropharmacology Business Unit

Retrieved on: 
Thursday, November 30, 2023
Research, Finance, Neurology, Clinical Trials, Professional Services, Health, Pharmaceutical, Other Science, Science, CNS, Sale, Contract research organization, Lincoln International, Acquisition, Ropes & Gray, QPS, KPMG, Perella Weinberg Partners, Multimedia, Neuropharmacology, DSM-IV codes, L.E.K. Consulting, Drug discovery, CMC, EY, Czech Republic, Drug development, Pharmaceutical industry, Nordic

Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.

Key Points: 
  • Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.
  • QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
  • QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees.
  • We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” says Ben Chien, President and CEO of QPS Holdings, LLC.

Wendy Webber Nelson, PhD and Michael Patsalos-Fox Join SciShield's Board of Directors

Retrieved on: 
Monday, December 4, 2023
ARCH Venture Partners, QPS, Safety, SAN, Cognizant, Vidyo, Mid-America Regional Council, Health, McKinsey & Company, Doctor of Philosophy, Partnership, Management, Alkermes

SAN FRANCISCO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- SciShield, a leading provider of safety and regulatory compliance management software for scientific laboratories, today announced that Wendy Webber Nelson, PhD and Michael Patsalos-Fox have joined its Board of Directors. Both bring decades of experience in corporate leadership and the life sciences industry.

Key Points: 
  • SAN FRANCISCO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- SciShield, a leading provider of safety and regulatory compliance management software for scientific laboratories, today announced that Wendy Webber Nelson, PhD and Michael Patsalos-Fox have joined its Board of Directors.
  • "I am excited to welcome Dr. Wendy Webber Nelson and Michael Patsalos-Fox to the SciShield Board of Directors.
  • Wendy and Michael bring a depth of expertise and customer focus that's truly inspiring, said Nathan Watson, Founder & CEO of SciShield.
  • "We're thrilled to welcome Wendy and Michael to the SciShield Board of Directors," said Neil Willis, member of the SciShield Board of Directors and Partner at Strattam Capital.

Dr Tim Ballance Promoted to President of Infleqtion UK

Retrieved on: 
Monday, October 30, 2023
Data analysis, Optimal design, GPS, Innovation, Doctor of Philosophy, University, Master of Science, Research, Innovate UK, Artificial intelligence, Satellite navigation, GNSS, QPS, Growth, Imperial College London, Qinetiq, Telecommunications, Physics, AI, Forest Law Enforcement and Governance Program, Medical device, Management

OXFORD, England, Oct. 30, 2023 /PRNewswire/ -- Infleqtion, the world's quantum information company, is delighted to announce the promotion of Dr Tim Ballance to President of Infleqtion UK.

Key Points: 
  • OXFORD, England, Oct. 30, 2023 /PRNewswire/ -- Infleqtion, the world's quantum information company, is delighted to announce the promotion of Dr Tim Ballance to President of Infleqtion UK.
  • Dr Ballance has been a pivotal figure in Infleqtion's journey since the establishment of its Oxford office in 2015 when he joined as Lead Scientist.
  • Before joining Infleqtion, he worked as a post-doctoral researcher in quantum computing at the University of Oxford.
  • Infleqtion UK has won many research awards, including High-BIAS2 (High-Bandwidth Inertial Atom Source) and PICAS (Photonically Integrated Cold Atom Source).

Cadent Introduces Aperture MX to Directly Connect Advertisers and Publishers

Retrieved on: 
Wednesday, October 18, 2023
DOOH, Cadent, MX, CTV, SVP, Aperture, Advertising, QPS, Growth, Cadent Gas, Basis Technology, Ecosystem, Entertainment Studios, OLV, Video game, Camera, Television

The newest product within Cadent Aperture Platform, MX increases transparency between publishers and advertisers, makes it easier to activate and optimize cross-screen campaigns, and gives publishers the ability to generate more revenue through Cadent's extensive demand-side relationships.

Key Points: 
  • The newest product within Cadent Aperture Platform, MX increases transparency between publishers and advertisers, makes it easier to activate and optimize cross-screen campaigns, and gives publishers the ability to generate more revenue through Cadent's extensive demand-side relationships.
  • "Aperture MX responds to these challenges by bridging the gap between advertisers and publishers with purpose-built, data-driven solutions."
  • Building on Cadent's traditional TV buying expertise and cutting-edge programmatic technology, Aperture MX provides advertisers with premium inventory sourced directly from the publisher.
  • Aperture Viewer Graph connects devices to households, enabling cookieless optimizations for buy-side audiences across Aperture MX to deliver greater scale and precision against an advertiser's target audience.

Baidu AI Cloud Leads China Market for Fourth Year in a Row with 69.7% Growth in 2022, Report Says

Retrieved on: 
Wednesday, July 26, 2023
Cloud, IDC, Natural language processing, BIDU, Geely, Baidu, State Grid Corporation of China, Shanghai Pudong Development Bank, Research, OCR, HKEX, QPS, Artificial intelligence, Yoy, Growth, Taikang Life Insurance, AI, Ecosystem, ERNIE, Medical device, Cryptocurrency

The report foresees the rapid development of large models and generative AI in the next 3-5 years, positioning Baidu AI Cloud for promising opportunities to further bolster its growth.

Key Points: 
  • The report foresees the rapid development of large models and generative AI in the next 3-5 years, positioning Baidu AI Cloud for promising opportunities to further bolster its growth.
  • IDC observed China's AI public cloud service market has experienced remarkable 80.6% year-on-year growth, reaching a market size of 7.973 billion yuan by the end of 2022.
  • Baidu AI Cloud has consistently held the top market position in IDC's biannual rankings since 2019, now marking the eighth consecutive time it has led the ranking.
  • Analyzing the achievements of Baidu AI Cloud, the IDC report attributes its success to the comprehensive breadth of the company's AI solution, which includes self-developed chips, framework, and a wide range of AI capabilities.